ImmunityBio’s ANKTIVA & FDA Expanded Access: Transforming bladder cancer treatment

At ASCO 2025, ImmunityBio’s chief medical officer, Dr Sandeep Reddy, spoke with pharmaphorum about the importance of FDA Expanded Access authorisation for its Cancer BioShield platform, anchored by ANKTIVA.

Dr Reddy discussed the US scene, but also the status of ANKTIVA in the UK and EU, as well as the importance of this offering in BCG-unresponsive non-muscle invasive bladder cancer with CIS with or without papillary tumours, as well as the potential of ANKTIVA in other indications.

Watch this and other conversations from ASCO 2025 here.